Autologous Bone Marrow transplantation - Blog Science Connections

More documents

Recommendations

Info

606 ABMT in Wilms' Tumor: An EBMT Survey US (6) have provided valuable indications regarding factors associated with a risk of responding poorly or relapsing. Unfavourable histology, extension of the disease at onset, size of the tumor, location of relapse have been identified as prognostic factors. For these poor risk patients, a search for more effective treatments appears justified. The efficacy of high-dose chemotherapy with autologous bone marrow rescue has been considered by several investigators and in this report we have tried to summarize preliminary information. The meaning of the data is somehow reduced by the heterogeneous criteria adopted to elect patients to high dose chemotherapy and by the different ablative regimens employed. However most investigators independently agreed to use Melphalan (7) in combination with Vincristine or a podophillin derivative. Only few considerations can be made regarding the potential efficacy of high dose chemotherapy in improving the outcome of children with poor-risk Wilms' tumor: 1) Both cases with measurable tumor lesions responded and achieved CR although of short duration. 2) The three stage IV patients treated in first CR continue to be in CR after a follow-up of more than 20 months. 3) Five of the 15 patients who received high dose chemotherapy in a second or further CR maintain CR with a median observation time of 23 months. 4) Overall toxicity encountered in this series of patients appears similar to that in children treated for other malignancies (8). However the two cases, one of transient impairment of renal function and one of chronic insufficiency observed in this group of nephrectomized patients suggest that the residual kidney may be abnormally susceptible to drug damages. Finally the two deaths from pneumonitis, both occuring in the group of 9 children who had been previously irradiated to the lungs, confirm that this last treatment modality is associated with increased risk of developing lung complications (9-10). CONCLUSIONS High dose chemotherapy regimens are feasible in poor prognosis Wilms' tumor. Special attention has to be given to the possibly increased risk of these patients to develop renal and lung toxicities. A definite conclusion on the potential role of high-dose chemotherapy in improving the outcome of children with poor risk Wilms' tumor cannot be given on the basis of the few cases treated so
ABMT in Wilms' Tumor: An EBMT Survey 607 far, of the heterogeneous criteria of eligibility and of the regimens adopted. A well-designed multicenter study appears desirable to clarify this important issue. REFERENCES 1. D'Angio GJ, Evans AE: Cancer 38:633;1976. 2. Jereb B., Tournade MF: Cancer 45:1632;1980. 3. Appelbaum FR, Sullivan KM: J Clin Oncol 5:1340,1987. 4. Johnson DB, Thompson JM: J of Clin Oncol 5:783,1987. 5. Jereb B, Isaac R: Eur Paediatr Haematol Oncol 2:71;1985. 6. Breslow NE, Churchill G, Cancer 58:2501;1986. 7. Prats J, De Toledo JS: International Society of Paediatric Oncology SIOP XVII Meeting, Venice 1985, p. 289. 8. Philip T, Bernard JL: J Clin Oncol 5:266;1987. 9. Kim TH, Rybka WB: Int J Radiation Oncology Biol Phys 11:1285;1985. 10. Bey P. Renal Tumors: Proceedings of the First International Symposium on Kidney Tumors; New York, Alan R. Liss, 1981, p. 97.
Page 1:
Autologous Bone Marrow transplantat
Page 5 and 6:
AUTOLOGOUS BONE MARROW TRANSPLANTAT
Page 7 and 8:
Contents Preface xxi Acknowledgment
Page 9 and 10:
High Dose Etoposide, Melphalan, Tot
Page 11 and 12:
High-Dose Therapy and Autologous Bo
Page 13 and 14:
Autologous Bone Marrow Transplantat
Page 15 and 16:
Breast Tumor Cell Detection in Marr
Page 17 and 18:
High Dose Chemo-Radiotherapy with B
Page 19 and 20:
The Use of Recombinant Human Granul
Page 21:
Session VIII - Further Developments
Page 25:
Acknowledgments Publication of thes
Page 29 and 30:
CBV and ABMT for AML in CRI 3 DOES
Page 31 and 32:
CBV and ABUT for AML in CR1 5 Bone
Page 33 and 34:
CBV and ABMT for AML in CR1 7 27 36
Page 35 and 36:
CBV and ABMT for AML in CR1 Table 3
Page 37 and 38:
CBV and ABMT for AML in CRI 11 ACKN
Page 39 and 40:
Mafosfamide Purging in Acute Leukem
Page 41 and 42:
Page 43 and 44:
Page 45 and 46:
Page 47 and 48:
Timing of BMT for ANL 21 TIMING OF
Page 49 and 50:
Timing of BMT for ANL 23 Unlike che
Page 51 and 52:
Timing of BMT for ANL 25 autologous
Page 53 and 54:
Timing of Bone Marrow Transplantati
Page 55 and 56:
Merocyanine-540 and Mafosfamide Pur
Page 57 and 58:
Merocyanine-540 and Mafosfamide Pur
Page 59:
Merocyaniñe-540 and Mafosfamide Pu
Page 62 and 63:
Sensitivity of Leukemic Progenitors
Page 64 and 65:
38 Sensitivity of Leukemic Progenit
Page 67 and 68:
ABMT for Consolidation of AML/ALL i
Page 69 and 70:
Page 71 and 72:
Page 73 and 74:
Page 75 and 76:
Page 77 and 78:
Page 79:
Page 82 and 83:
56 Hematopoietic Progenitor Selecti
Page 84 and 85:
Page 86 and 87:
Page 88 and 89:
62 Acute Leukemia - AML (Purging) (
Page 90 and 91:
64 Acute Leukemia - AML (Purging) T
Page 93 and 94:
4HC/VCR Chemopurge 67 CHEMOPURGE WI
Page 95 and 96:
4HC/VCR Chemopurge 69 Table 1. Pati
Page 97 and 98:
4HC/VCR Chemopurge 71 remain in rem
Page 99 and 100:
Autologous BMT for ANLL 73 AUTOLOGO
Page 101 and 102:
Autologous BMT for ANLL 75 Hematolo
Page 103 and 104:
Autologous BMT for ANLL 77 in CR2 o
Page 105 and 106:
Clinical Value of Auto BMT 79 Discu
Page 107 and 108:
BAVC and ABMT in AML Patients 81 BA
Page 109 and 110:
BAVC and ABMT in AML Patients 83 Bo
Page 111 and 112:
BAVC and ABMT in AML Patients 85 Ta
Page 113 and 114:
ABMT in Advanced ALL 87 RESULTS OF
Page 115 and 116:
ABMT in Advanced ALL 89 After hemat
Page 117:
ABMT in Advanced ALL 91 Two differe
Page 120 and 121:
94 Autograft for AML Since no concl
Page 122 and 123:
96 Autograft for AML 8 16 24 32 40
Page 124 and 125:
98 Autograft for AML relapse free p
Page 127 and 128:
Etoposide, Melphalan, TBI and ABMT
Page 129 and 130:
Page 131:
Page 134 and 135:
108 J In Vitro/In Vivo Treatment of
Page 136 and 137:
110 In Vitro/In Vivo Treatment of L
Page 138 and 139:
112 In Vitro/In Vivo Treatment of L
Page 140 and 141:
114 BU/CY in BMT CY alone is not an
Page 142 and 143:
116 BU/CY in BMT BU CY PREPARATIVE
Page 144 and 145:
118 BU/CY in BMT autologous or allo
Page 146 and 147:
120 Double AML Transplants consolid
Page 148 and 149:
122 Double AML Transplants 100 Even
Page 150 and 151:
124 Double AML Transplants There is
Page 152 and 153:
126 Double Transplants and 21 had a
Page 154 and 155:
128 Double Transplants (ALL) and fu
Page 156 and 157:
130 Double Transplants PROSPECTIVE
Page 158 and 159:
132 Double Transplants months (22-7
Page 161 and 162:
Autologous vs. Allogeneic Transplan
Page 163:
SESSION I - LEUKEMIA B. ACUTE LEUKE
Page 166 and 167:
140 ABMT vs. Chemotherapy in High R
Page 168 and 169:
Page 170 and 171:
Page 172 and 173:
146 Marrow Transplantation for ALL
Page 174 and 175:
148 Marrow Transplantation for ALL
Page 177 and 178:
ABMT Italian Study for Childhood AL
Page 179 and 180:
ABMT Italian Study for Childhood AL
Page 181 and 182:
Autologous Transplant for ALL 155 A
Page 183 and 184:
Autologous Transplant for ALL 157 R
Page 185 and 186:
Autologous Transplant for ALL 159 n
Page 187 and 188:
ABMT in ALL 161 AUTOLOGOUS BONE MAR
Page 189 and 190:
ABMT in ALL 163 10< 5
Page 191 and 192:
ABMT in ALL 165 NATIONAL SWEDISH AL
Page 193 and 194:
ABMT in ALL 167 AUTOLOGOUS BONE MAR
Page 195:
ABMT in ALL 169 98 X tlx 7IX (IX SI
Page 198 and 199:
172 B43/CD19 PAP IT Table 1. Expres
Page 200 and 201:
174 B43/CD19 PAP IT dialyzed, and f
Page 202 and 203:
Figure 2. Biochemical Analysis of B
Page 204 and 205:
178 B43/CD19 PAP IT 15. Uckun FM, K
Page 206 and 207:
180 Detection of Minimal Residual D
Page 208 and 209:
Page 210 and 211:
Page 212 and 213:
Page 214 and 215:
188 Autologous BMT vs. Chemotherapy
Page 216 and 217:
190 Autologous BMT vs. Chemotherapy
Page 218 and 219:
192 Autologous vs. Allogeneic Trans
Page 220 and 221:
194 Timing & Conditioning Regimens
Page 222 and 223:
196 Timing & Conditioning Regimens
Page 225 and 226:
Purging with Anti-B Cell MoAb and C
Page 227 and 228:
Page 229 and 230:
NO o 1—* c\i (M (M *— irt o •
Page 231 and 232:
Page 233 and 234:
Front Line Chemotherapy Regimens 20
Page 235 and 236:
•o tí id O IN GO ai o- CD «-
Page 237 and 238:
CA CA 3 CU 4-» CD > t_ *-> CD C/l
Page 239 and 240:
Page 241:
Page 244 and 245:
218 Optimal Timing for ABMT in Non-
Page 246 and 247:
Page 248 and 249:
Page 251 and 252:
ABMT in NHL and HD — Timing of Th
Page 253 and 254:
ABMT in NHL and HD - - Timing of Th
Page 255 and 256:
ABUT in NHL and HD — Timing of Th
Page 257 and 258:
The Role of Intensive Chemotherapy
Page 259 and 260:
(H S m ¡3 < Xi •P •ri Se X tri
Page 261 and 262:
Page 263 and 264:
Page 265:
Page 268 and 269:
242 Optimal Timing for Intermediate
Page 270 and 271:
244 Optimal Timing for Intermediate
Page 273 and 274:
BMT for Lymphoblastic Lymphoma 247
Page 275 and 276:
Page 277 and 278:
Page 279 and 280:
High Dose Therapy for Multiple Myel
Page 281 and 282:
Page 283 and 284:
Page 285 and 286:
Page 287 and 288:
Hodgkin's Disease, ABMT 261 OPTIMAL
Page 289 and 290:
Hodgkin's Disease, ABMT 263 Table 1
Page 291 and 292:
Hodgkin's Disease, ABMT 265 Table 3
Page 293:
Hodgkin's Disease, ABMT 267 REFEREN
Page 296 and 297:
270 Timing of ABMT in Hodgkin's Dis
Page 298 and 299:
272 Timing of ABMT in Hodgkin's Dis
Page 301 and 302:
Timing of CBV and Autologous BMT 27
Page 303 and 304:
Page 305 and 306:
Page 307 and 308:
Page 309:
Page 312 and 313:
286 High Dose Chemotherapy Regimens
Page 314 and 315:
Page 316 and 317:
Page 319 and 320:
Optimal Timing for Lymphoblastic Ly
Page 321:
Optimal Timing for Lymphoblastic Ly
Page 324 and 325:
298 Optimal Timing for Hodgkin's TB
Page 326 and 327:
300 BMT Preparative Regimens marrow
Page 328 and 329:
302 BMT Preparative Regimens As can
Page 331 and 332:
Conditioning for AuBMT in NHL 305 A
Page 333 and 334:
Conditioning for AuBMT in NHL 307 T
Page 335 and 336:
Conditioning for AuBMT in NHL 309 e
Page 337 and 338:
Escalating Dose CBV in Lymphoma 311
Page 339 and 340:
Page 341:
Page 344 and 345:
318 High Dose Chemotherapy with ABM
Page 346 and 347:
Page 348 and 349:
3 CD + i— ro
Page 350 and 351:
Page 353 and 354:
ABMT in Low Grade NHL 327 AUTOLOGOU
Page 355 and 356:
ABMT in Low Grade NHL 329 ABMT Foll
Page 357 and 358:
Purging and Relapse in BL 331 EX-VI
Page 359 and 360:
CD "O + >- CO CU c/l TJ a. CO CI C
Page 361 and 362:
CO u- 3 < H CD < £ £¡ cf 25 3 <
Page 363 and 364:
Purging and Relapse in BL 337 BM af
Page 365 and 366:
Detection of MRD by PCR 339 DETECTI
Page 367 and 368:
Detection of MRD by PCR 341 Figure
Page 369:
Detection of MRD by PCR 343 results
Page 372 and 373:
346 Conditioning Regimens in Lympho
Page 374 and 375:
348 Conditioning Regimens in Lympho
Page 377:
Studies in Indolent Lymphoma 351 Di
Page 380 and 381:
354 Detection of Disease & Purging
Page 383 and 384:
ABMT as Intensification in Breast C
Page 385 and 386:
ABMT as Intensification in Breast C
Page 387:
AB MT as Intensification in Breast
Page 390 and 391:
364 Breast Cancer: Autologous Bone
Page 392 and 393:
366 Breast Cancer: Autologous Bone
Page 394 and 395:
368 High Dose Chemotherapy in Breas
Page 396 and 397:
370 High Dose Chemotherapy in Breas
Page 398 and 399:
372 High Dose Consolidation in Brea
Page 400 and 401:
Page 402 and 403:
Page 404 and 405:
378 STAMP Studies in Breast Cancer
Page 406:
CO •p fi 0) •rl •P id tU o o
Page 409:
STAMP Studies in Breast Cancer 383
Page 412 and 413:
386 Solid Tumors I: Breast clearly
Page 414 and 415:
388 Solid Tumors I: Breast cannot i
Page 416 and 417:
390 Dose Intensification for the Tr
Page 418 and 419:
Page 420 and 421:
Page 422 and 423:
Page 425 and 426:
High-Dose Intensification for Breas
Page 427 and 428:
Page 429:
Page 432 and 433:
406 ABMT and Hematopoietic Recovery
Page 434 and 435:
Page 436 and 437:
Page 439 and 440:
Bone Marrow Metastases in Small Cel
Page 441 and 442:
Page 443 and 444:
Page 445:
Page 448 and 449:
422 Occult Tumor in Bone Marrow RES
Page 450 and 451:
424 Occult Tumor in Bone Marrow Tab
Page 453 and 454:
Breast Tumor Cell Detection 427 BRE
Page 455 and 456:
Breast Tumor Cell Detection 429 Nex
Page 457 and 458:
Breast Cancer 431 Discussion 2 - Se
Page 459:
Breast Cancer 433 Dr. Peters: We we
Page 463 and 464:
Various Treatments in Gliomas 437 H
Page 465 and 466:
Various Treatments in Gliomas 439 T
Page 467 and 468:
Various Treatments in Gliomas 441 T
Page 469 and 470:
Various Treatments in Gliomas 443 (
Page 471 and 472:
Various Treatments in Gliomas 445 G
Page 473:
Various Treatments in Gliomas 447 d
Page 476 and 477:
m í. o O ._• E CU c I co CJ M X
Page 478 and 479:
452 ABMT in Pediatric Brain Tumors
Page 480 and 481:
454 ABMT in Pediatric Brain Tumors
Page 483 and 484:
Adjuvant High-Dose BCNU and BMT for
Page 485 and 486:
Page 487:
Page 490 and 491:
464 Gliomas Dr. Biron: It is so dif
Page 492 and 493:
466 Gliomas Dr. Biron: Among the 16
Page 495 and 496:
ABMT for Germ Cell Tumors 469 HIGH-
Page 497 and 498:
ABMT for Germ Cell Tumors 471 Table
Page 499 and 500:
ABMT for Germ Cell Tumors 473 Group
Page 501 and 502:
ABMT for Germ Cell Tumors 475 CONCL
Page 503 and 504:
Massive Chemotherapy in NSGCT 477 C
Page 505 and 506:
Massive Chemotherapy in NSGCT 479 N
Page 507 and 508:
Massive Chemotherapy in NSGCT 481 T
Page 509 and 510:
Massive Chemotherapy in NSGCT 483 T
Page 511 and 512:
Massive Chemotherapy in NSGCT 485 1
Page 513 and 514:
CBDCA/VP-16 in Germ-Cell Cancer 487
Page 515 and 516:
Page 517:
Page 520 and 521:
494 Testicular Cancer Dr. Biron: Ho
Page 522 and 523:
496 Testicular Cancer Dr. Sorzsky:
Page 525 and 526:
ABMT for Advanced Melanoma 499 TREA
Page 527 and 528:
ABMT for Advanced Melanoma 501 Tabl
Page 529 and 530:
ABMT for Advanced Melanoma 503 Tabl
Page 531 and 532:
ABMT for Advanced Melanoma 505 agen
Page 533:
SESSION III - SOLID TUMORS F. OVARI
Page 536 and 537:
510 HDM and ABMT in Ovarian Carcino
Page 538 and 539:
Page 540 and 541:
Page 543:
SESSION III - SOLID TUMORS G. PHASE
Page 546 and 547:
520 High Dose Carboplatin TREATMENT
Page 548 and 549:
522 High Dose Carboplatin ABMT. In
Page 551 and 552:
G.I. Tumors 525 Discussion 5 - Sess
Page 553:
SESSION IV - PEDIATRIC TUMORS A. NE
Page 556 and 557:
530 Treatment of Metastatic Neurobl
Page 558 and 559:
Page 560 and 561:
Page 562 and 563:
Page 564 and 565:
Page 566 and 567:
Page 569 and 570:
BMT in Neuroblastoma 543 HIGH DOSE
Page 571 and 572:
BMT in Neuroblastoma 545 lOO-i —1
Page 573 and 574:
BMT in Neuroblastoma 547 100 SURVIV
Page 575 and 576:
ABMT in Neuroblastoma 549 AUTOLOGOU
Page 577 and 578:
O ° 4> o O ÍM -o o 00 o o in O (\
Page 579 and 580:
ABMT in Neuroblastoma 553 antibodie
Page 581 and 582: •p (0 CT« O +J < 03 i) •H « c
Page 583: ABMT in Neuroblastoma 557 6. Favrot
Page 586 and 587: 560 Myeloablative Treatment for Chi
Page 594 and 595: 568 AutoBMT for Neuroblastoma at CH
Page 601 and 602: Neuroblastoma with Intensive Therap
Page 609: Neuroblastoma with Intensive Therap
Page 612 and 613: 586 Neuroblastoma Dr. Philip: We us
Page 614 and 615: 588 Neuroblastoma Dr. Graham-Pole:
Page 616 and 617: 590 Neuroblastoma they saw relapses
Page 619 and 620: Ewing's Sarcoma Phase II Metastases
Page 625: Ewing's Sarcoma Phase II Metastases
Page 628 and 629: n o + + + + + + to in •O CM CM CM
Page 630 and 631: 604 ABMT in Wilms' Tumor: An EBMT S
Page 635 and 636: Consolidation Therapy in Metastatic
Page 641: Consolidation Therapy in Metastatic
Page 644 and 645: 618 ABMT in Pediatric Sarcomas chem
Page 646 and 647: 620 ABMT in Pediatric Sarcomas risk
Page 648 and 649: 622 Sarcoma Dr. Seeger: These marro
Page 651 and 652: Effects of IL-1 on Hematopoiesis 62
Page 653 and 654: Effects of IL-1 on Hematopoiesis 62
Page 655: Effects of IL-1 on Hematopoiesis 62
Page 658 and 659: 632 rhGM-CSF After Marrow Transplan
Page 664 and 665: 638 IL-1 as Protection from Toxic E
Page 671 and 672: Growth Factor Therapy in Primates 6
Page 677 and 678: Differences Between Normal and Leuk
Page 683 and 684:
rHuGM-CSF in Autologous Bone Marrow
Page 685 and 686:
HuGM-CSF in Autologous Bone Marrow
Page 687 and 688:
Page 689 and 690:
Page 691 and 692:
Page 693:
Page 696 and 697:
670 Growth Factors document all of
Page 699 and 700:
Growth Factors 673 Discussion 2 - S
Page 701:
SESSION VI - PERIPHERAL BLOOD STEM
Page 704 and 705:
678 GM-CSF and PB Progenitor Cells
Page 706 and 707:
Page 708 and 709:
Page 711 and 712:
Peripheral Blood CFU-GM and BFUe 68
Page 713 and 714:
Page 715 and 716:
Page 717 and 718:
Page 719 and 720:
Occult Tumor in Apheresis Harvests
Page 721 and 722:
Occult Tumor in Apheresis Harvests
Page 723 and 724:
Stern Cell Collection and Toxicity
Page 725 and 726:
Page 727:
Page 730 and 731:
704 Lymphoma and PSCT harvest. The
Page 732 and 733:
706 Lymphoma and PSCT DISCUSSION Th
Page 734 and 735:
708 PBSC Transplants in Solid Tumor
Page 736 and 737:
Page 738 and 739:
Page 740 and 741:
714 Autologous Blood Stem Cell Tran
Page 742 and 743:
716 Autologous Blood Stem Cell Tran
Page 745 and 746:
Peripheral Blood Stem Cells 719 TUM
Page 747 and 748:
Peripheral Blood Stem Cells 721 eig
Page 749 and 750:
Myeloablative Treatments in Haemato
Page 751 and 752:
Page 753 and 754:
Page 755 and 756:
Page 757:
Page 760 and 761:
734 Peripheral Blood Stem Cells Dr.
Page 762 and 763:
Page 764 and 765:
Page 766 and 767:
Page 769 and 770:
Treatment of Cytomegalovirus Pneumo
Page 771 and 772:
Treatment of Cytomegalovirus Pneumo
Page 773 and 774:
Viral Infection in BMT 747 VIRAL IN
Page 775 and 776:
Viral Infection in BMT 749 Table 1.
Page 777:
Viral Infection in BMT 751 REFERENC
Page 780 and 781:
754 IV+PO Ig in ABMT incidence of i
Page 782 and 783:
756 IV+PO Ig in ABMT Table 2. Posit
Page 784 and 785:
758 IV+PO Ig in ABMT Approaches for
Page 786 and 787:
760 Supportive Care away with that.
Page 789 and 790:
Merocyanine 540 763 MEROCYANINE 540
Page 791 and 792:
Merocyanine 540 765 Table 1. Merocy
Page 793:
Merocyanine 540 767 9. Kalyanaraman
Page 796 and 797:
770 Purging with Aldophosphamide Ac
Page 798 and 799:
Page 800 and 801:
Page 802 and 803:
Page 805 and 806:
Further Developments in Purging 779
Page 807 and 808:
Page 809:
Page 812 and 813:
786 Further Developments in Purging
Page 814 and 815:
Page 816 and 817:
Page 819 and 820:
PARMA International Protocol 793 PA
Page 821 and 822:
PARMA International Protocol 795 Wk
Page 823 and 824:
PARMA International Protocol 797 gr
Page 825 and 826:
Double ABMT in Advanced Neuroblasto
Page 827 and 828:
Page 829 and 830:
Page 831:
Page 834 and 835:
808 General Discussion to pathologi
Page 837:
SUMMARY
Page 840 and 841:
814 Autotransplants: Acute Leukemia
Page 842 and 843:
576 Autotransplants: Acute Leukemia
Page 845 and 846:
819 Contributors and Participants M
Page 847 and 848:
821 Kenneth A. Ault, Maine Cytometr
Page 849 and 850:
823 B. J. Bolwell, Cleveland Clinic
Page 851 and 852:
825 Myra W. Chang, Department of He
Page 853 and 854:
827 J. Crown, Memorial Sloan-Ketter
Page 855 and 856:
829 Carol L. Epstein, Immunex Resea
Page 857 and 858:
831 Maria Vittoria Gazzola, Unita 1
Page 859 and 860:
833 Mildred S. Hanson, Tumor Immuno
Page 861 and 862:
835 Herbert Kaizer, Rush-Presbyteri
Page 863 and 864:
837 Eric Lepage, Institut d 1 Hemat
Page 865 and 866:
839 Michel Marty, Département de C
Page 867 and 868:
841 J. Myers, Memorial Sloan-Ketter
Page 869 and 870:
843 C. R. Pinkerton, Department of
Page 871 and 872:
845 Rein Sarai, The Johns Hopkins U
Page 873 and 874:
847 J. J. Sotto, C.H.R.U. Orenoble,
Page 875 and 876:
849 Guido Tricot, Department of Med
Page 877:
851 J.R. Zucali, Department of Medi
show all

Autologous Bone Marrow transplantation - Blog Science Connections

Create successful ePaper yourself

Delete template?

Save as template?